Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48%…
TARRYTOWN, N.Y., May 21, 2022 - Children already on other lipid-lowering therapies entered the!-->…
TARRYTOWN, N.Y., May 21, 2022 - Children already on other lipid-lowering therapies entered the!-->…
Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating!-->…
Welcome, Login to your account.
Welcome, Create your new account
A password will be e-mailed to you.